Predict your next investment

Advisory
cormorant-capital.com

See what CB Insights has to offer

Investments

8

Portfolio Exits

6

About Cormorant Capital

Cormorant Capital co-invests in select transactions and also advises clients on strategic equity solutions for new transactions and existing portfolios.

Cormorant Capital Headquarter Location

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Cormorant Capital News

Freenome Inks $300M Series D Round

Dec 7, 2021

This brings the company's total financing to over $800 million since the company was founded in 2014. This round of financing was led by investors Perceptive Advisors and RA Capital Management, joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society's BrightEdge Ventures, Artis Ventures, Bain Capital Life Sciences, Catalio Capital Management, Cormorant Capital, DCVC, Farallon Capital Management, Fidelity Management and Research Company LLC, GV, Janus Henderson Investors, Kaiser Permanente, Novartis, Polaris Partners, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, with funds and accounts advised by T. Rowe Price Associates, Inc. In addition, there were several new biotech institutional investors well-placed to support the company's mission including ArrowMark Partners, Byers Capital, Eventide Asset Management LLC, HBM Healthcare Investments, Intermountain Ventures, Logos Capital, Pura Vida Investments, Suvretta Capital Management, and other undisclosed funds. Freenome is a biotechnology company with a comprehensive multiomics platform for early cancer detection using a routine blood draw. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

Cormorant Capital Investments

8 Investments

Cormorant Capital has made 8 investments. Their latest investment was in Shoreline Biosciences as part of their Series A on April 4, 2021.

CBI Logo

Cormorant Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/7/2021

Series A

Shoreline Biosciences

$43M

Yes

2

1/9/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/9/2020

Series D

Subscribe to see more

$99M

Subscribe to see more

10

10/15/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

6/5/2020

Series C - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/7/2021

1/9/2021

11/9/2020

10/15/2020

6/5/2020

Round

Series A

Series B

Series D

Series A

Series C - II

Company

Shoreline Biosciences

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$43M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

10

10

Cormorant Capital Portfolio Exits

6 Portfolio Exits

Cormorant Capital has 6 portfolio exits. Their latest portfolio exit was VectivBio on April 09, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/9/2021

IPO

$99M

1

3/12/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/9/2020

IPO

Subscribe to see more

Subscribe to see more

10

2/13/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/25/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/9/2021

3/12/2021

10/9/2020

2/13/2020

10/25/2019

Exit

IPO

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.